| Name | Title | Contact Details |
|---|---|---|
John Lamoureux |
Director, Global IT Infrastructure and Security | Profile |
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite`s strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. Elite has four ANDA products partnered with TAGI Pharma; one ANDA has launched, two ANDAs are in the process of a manufacturing site transfer and an additional ANDA is currently under review by the FDA. Elite also manufactures Lodrane D® and receives royalties for Lodrane D®, an allergy product partnered with ECR Pharmaceuticals (“ECR”), a wholly owned subsidiary of Hi-Tech Pharmacal (“Hi-Tech”). Elite`s lead pipeline products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also has partnered with Mikah Pharma to develop a new product and with Hi-Tech Pharmacal to develop an intermediate for a generic product.
Sunovion Pharmaceuticals Inc. leads the way to a healthier tomorrow by creating medicines for respiratory diseases and central nervous system disorders.
AustarPharma, LLC is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
QoL Meds is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cannara plans to operate the largest indoor medical cannabis biotech facility in Quebec.